search
Back to results

Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers

Primary Purpose

Tongue Cancer, Tongue Cancer TNM Staging Primary Tumor (T) T1, Tongue Cancer TNM Staging Primary Tumor (T) T2

Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers
1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers
Sponsored by
Samsung Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tongue Cancer focused on measuring Tongue cancer, Surgery, Safety margin

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pathologically proven oral tongue squamous cell carcinoma
  • Stage cT1-2N0M0 tumors
  • Treatment-naïve tumor
  • American Society of Anesthesiologists (ASA) physical status classification 1-3.
  • Patients who give a written informed consent voluntarily.

Exclusion Criteria:

  • cT3-4 or N(+) tumors
  • Recurrent tumors or salvage surgery
  • Patients who have had a previous head and neck surgery and radiation treatment.
  • Patients who have other head and neck cancer, within the last 5 years.

Sites / Locations

  • Samsung Medical CenterRecruiting
  • Asan Medical Center
  • Seoul National University Hospital
  • Ajou university School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Wide surgical safety margin

Narrow surgical safety margin

Arm Description

1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer

1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer

Outcomes

Primary Outcome Measures

2 year local control rate
At 2 years after the completion of treatment, % of local control (or recurrence rate)

Secondary Outcome Measures

5 year recurrence free survival
5 year disease control rate
Speech function
Articulation score A seven-point articulation score (7: Within normal limits, 6 Mild-slight distortion and imprecision of consonants only, 5: Mild to moderate-all consonants targeted, 4: Moderate- at least 2 consonants placements acoustically distant from the target, 3: Moderate to marked-consonants and vowels both affected, 2: Marked- uses adaptive compensatory articulation for all lingual consonants, 1: Severe- does not use effective compensatory articulations) Reference: An objective assessment of speech and swallowing following free flap reconstruction for oral cavity cancers. Br J Plastic Surg 1996;49:363-9.
Swallowing function
Swallowing performance status score. A seven-point swallowing performance scale (1: Normal, 2: Within functional limits, 3: Mild impairment, 4, Mild-moderate, 5, Moderate, 6: Moderate-severe, 7: Severe impairment). (Reference: Swallowing Function in Patients With Head and Neck Cancer Prior to Treatment Arch Otolaryngol Head Neck Surg. 2000;126(3):371-377.)

Full Information

First Posted
January 31, 2021
Last Updated
May 3, 2022
Sponsor
Samsung Medical Center
Collaborators
Seoul National University Hospital, Asan Medical Center, Ajou University School of Medicine, National Cancer Center, Korea, Inje University, Seoul National University Bundang Hospital, Kangbuk Samsung Hospital, Dong-A University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04738786
Brief Title
Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers
Official Title
Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers: A Prospective Multicenter Randomized Non-inferiority Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 18, 2021 (Actual)
Primary Completion Date
December 31, 2028 (Anticipated)
Study Completion Date
December 31, 2030 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Samsung Medical Center
Collaborators
Seoul National University Hospital, Asan Medical Center, Ajou University School of Medicine, National Cancer Center, Korea, Inje University, Seoul National University Bundang Hospital, Kangbuk Samsung Hospital, Dong-A University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A prospective multicenter randomized non-inferiority clinical trial, to evaluate the efficacy and safety of 1.0 cm-safety margin surgery, compared with 1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer Summary: A current standard primary treatment for oral tongue cancer is a curative surgical resection with/without adjuvant radiation treatments (or chemoradiation). In pathological analysis of surgical specimens, more than 5 mm of non-tumorous tissues from the tumor border is regarded as a safe negative resection margin, according to the NCCN guideline (the National Comprehensive Cancer Network, Dec 10. 2020). To achieve this clear margin, surgeons are apt to use a 1.0 to 1.5 cm safety margin around the gross tumor during surgery, considering 30-50% tumor shrinkage in tissue fixation process. Many previous retrospective data have been reported to suggest the optimal or proper surgical extent for oral tongue cancer. Wider resection can lead to better local control, however, it sacrifices more normal tissue, resulting in the functional deficit of tongue (speech and swallowing), even with reconstruction. Unfortunately up to now, no prospective comparison of a different surgical safety margin for oral tongue cancer have been conducted to draw a more solid conclusion. Particularly in early stage oral tongue cancer (cT1-2N0), some study results have suggested that less than 5 mm resection margin in pathology specimens can be also safe and effective in terms of tumor control. To achieve a well-grounded result about the proper surgical safety margin in early stage (cT1-2N0) oral tongue cancer, we will compare the outcomes of the two (1.5 cm versus 1.0 cm) surgical safety margin in curative resection for cT1-2N0 oral tongue cancer.
Detailed Description
Randomization The randomized allocation table was made by stratified block randomization methods with 1:1 ratio according to each participating surgeon and tumor stage. Baseline number (BN) should be provided to the subjects in the order of the date of surgery. Surgical Procedure The study includes T1-2N0 oral tongue cancer patients. For the management of the primary lesion, wide resection with 1.0- or 1.5-cm surgical safety margin should be performed according to the results of study allocation. Neck management can be resection of primary tumor without neck dissection, with ipsilateral or bilateral neck dissection (guided by tumor location) or with sentinel lymph node biopsy, according to the NCCN guideline (version 1.2021). Evaluation of the surgical safety margin The surgical safety margin should be meticulously evaluated in the pathology specimens in all directions. The surgical margins less than 0.3 or 0.5 cm in final pathology results are considered as the close surgical margin. Adjuvant Treatment The adjuvant treatments either radiotherapy or chemoradiotherapy are conducted if indicated following the NCCN guideline. The follow-up after completion of the definitive treatment are made following the NCCN guideline. Efficacy evaluation The primary outcomes are determined with 2-year local control rates after the completion of the curative treatments. The secondary outcomes are determined with the 5-year disease-free survival rates and speech/articulation functional analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tongue Cancer, Tongue Cancer TNM Staging Primary Tumor (T) T1, Tongue Cancer TNM Staging Primary Tumor (T) T2, Surgery, Resection Margin, Squamous Cell Carcinoma
Keywords
Tongue cancer, Surgery, Safety margin

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A prospective multicenter randomized non-inferiority clinical trial, comparing two groups; 1.5 cm surgical safety margin versus 1.0 cm surgical safety margin in curative resection for cT1-2N0 oral tongue cancer
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
1358 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Wide surgical safety margin
Arm Type
Active Comparator
Arm Description
1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer
Arm Title
Narrow surgical safety margin
Arm Type
Active Comparator
Arm Description
1.0 cm safety margin surgery for cT1-2N0 oral tongue cancer
Intervention Type
Procedure
Intervention Name(s)
1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers
Intervention Description
Surgical resection including 1.5 cm normal tissue around the gross tumors Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side).
Intervention Type
Procedure
Intervention Name(s)
1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers
Intervention Description
Surgical resection including 1.0 cm normal tissue around the gross tumors
Primary Outcome Measure Information:
Title
2 year local control rate
Description
At 2 years after the completion of treatment, % of local control (or recurrence rate)
Time Frame
2 year
Secondary Outcome Measure Information:
Title
5 year recurrence free survival
Description
5 year disease control rate
Time Frame
5 year
Title
Speech function
Description
Articulation score A seven-point articulation score (7: Within normal limits, 6 Mild-slight distortion and imprecision of consonants only, 5: Mild to moderate-all consonants targeted, 4: Moderate- at least 2 consonants placements acoustically distant from the target, 3: Moderate to marked-consonants and vowels both affected, 2: Marked- uses adaptive compensatory articulation for all lingual consonants, 1: Severe- does not use effective compensatory articulations) Reference: An objective assessment of speech and swallowing following free flap reconstruction for oral cavity cancers. Br J Plastic Surg 1996;49:363-9.
Time Frame
2 year
Title
Swallowing function
Description
Swallowing performance status score. A seven-point swallowing performance scale (1: Normal, 2: Within functional limits, 3: Mild impairment, 4, Mild-moderate, 5, Moderate, 6: Moderate-severe, 7: Severe impairment). (Reference: Swallowing Function in Patients With Head and Neck Cancer Prior to Treatment Arch Otolaryngol Head Neck Surg. 2000;126(3):371-377.)
Time Frame
2 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathologically proven oral tongue squamous cell carcinoma Stage cT1-2N0M0 tumors Treatment-naïve tumor American Society of Anesthesiologists (ASA) physical status classification 1-3. Patients who give a written informed consent voluntarily. Exclusion Criteria: cT3-4 or N(+) tumors Recurrent tumors or salvage surgery Patients who have had a previous head and neck surgery and radiation treatment. Patients who have other head and neck cancer, within the last 5 years.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Han-Sin Jeong, MD PhD
Phone
82-2-3410-3579
Email
hansin.jeong@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jeon-Yeob Jang, MD PhD
Email
manup1377@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Han-Sin Jeong, MD PhD
Organizational Affiliation
Head and Neck Cancer Center, Samsung Medical Center, Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Han-Sin Jeong, MD, PhD
Phone
82-2-3410-3577
Email
hansin.jeong@samsung.com
First Name & Middle Initial & Last Name & Degree
Han-Sin Jeong, MD, PhD
Facility Name
Asan Medical Center
City
Seoul
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Youngho Chung
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eunjae Chung
Facility Name
Ajou university School of Medicine
City
Suwon
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeon Yeob Jang

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
The investigators will make our participant data available to other researchers after completion of this study.
Citations:
PubMed Identifier
27519352
Citation
Jang JY, Choi N, Ko YH, Chung MK, Son YI, Baek CH, Baek KH, Jeong HS. Differential Impact of Close Surgical Margin on Local Recurrence According to Primary Tumor Size in Oral Squamous Cell Carcinoma. Ann Surg Oncol. 2017 Jun;24(6):1698-1706. doi: 10.1245/s10434-016-5497-4. Epub 2016 Aug 12.
Results Reference
background

Learn more about this trial

Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers

We'll reach out to this number within 24 hrs